{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:48:31Z","timestamp":1776707311027,"version":"3.51.2"},"reference-count":163,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.reumae.2021.04.003","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T07:00:56Z","timestamp":1633158056000},"page":"317-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recommendations for prevention of infection in systemic autoimmune rheumatic diseases"],"prefix":"10.1016","volume":"18","author":[{"given":"\u00cd\u00f1igo","family":"R\u00faa-Figueroa Fern\u00e1ndez de Larrinoa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia E.","family":"Carreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9","family":"Brito Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"D\u00edaz del Campo Fontecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Pego Reigosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"G\u00f3mez Puerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela","family":"Ortega-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Tejera Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Aguado Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli\u00e1n","family":"Torre-Cisneros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Valencia-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Alejandra","family":"Pereda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Betina","family":"Nishishinya-Aquino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Ot\u00f3n S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Silva Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Maese Manzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Chamizo Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Correyero Plaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2021.04.003_bib0005","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10067-006-0441-9","article-title":"Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review","volume":"26","author":"Falagas","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0961203315627202","article-title":"Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis","volume":"25","author":"Lee","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.reumae.2021.04.003_bib0015","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.idc.2006.09.007","article-title":"Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis\/dermatomyositis","volume":"20","author":"Alarc\u00f3n","year":"2006","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.reumae.2021.04.003_bib0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/rheumatology\/key285","article-title":"Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides","volume":"58","author":"Garen","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0025","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/acr.22173","article-title":"Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies","volume":"66","author":"Yurkovich","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/00002281-200309000-00002","article-title":"Infectious complications in SLE after immunosuppressive therapies","volume":"15","author":"Kang","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00005792-198409000-00001","article-title":"Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency","volume":"63","author":"Ross","year":"1984","journal-title":"Medicine"},{"key":"10.1016\/j.reumae.2021.04.003_bib0040","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3899\/jrheum.131470","article-title":"Clinical and immunogenetic factors associated with pneumonia in patients with systemic lupus erythematosus: a case-control study","volume":"41","author":"R\u00faa-Figueroa","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.autrev.2018.09.001","article-title":"Prevalence of cervical HPV infection in women with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"18","author":"Garc\u00eda-Carrasco","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.reumae.2021.04.003_bib0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/acr.23015","article-title":"Comorbidities in patients with primary Sj\u00f6gren\u2019s syndrome and systemic lupus erythematosus: a comparative registries-based study","volume":"69","author":"R\u00faa-Figueroa","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.idc.2020.02.013","article-title":"Infections related to biologics: agents targeting B cells","volume":"34","author":"Leandro","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.reumae.2021.04.003_bib0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","article-title":"Alterations in immune function with biologic therapies for autoimmune disease","volume":"137","author":"Her","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001041","volume":"5","author":"Furer","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2021.04.003_bib0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0891-5520(05)70149-5","article-title":"Infections in systemic lupus erythematosus and rheumatoid arthritis","volume":"15","author":"Bouza","year":"2001","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.reumae.2021.04.003_bib0075","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/jvh.12302","article-title":"Low prevalence of hepatitis B virus infection in patients with autoimmune diseases in a Chinese patient population","volume":"21","author":"Sui","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.reumae.2021.04.003_bib0080","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00296-009-1188-9","article-title":"Low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus in southern China","volume":"30","author":"Zhao","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2021.04.003_bib0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semarthrit.2017.01.010","article-title":"Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus","volume":"47","author":"R\u00faa-Figueroa","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.04.003_bib0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0889-857X(02)00100-X","article-title":"Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis\/dermatomyositis","volume":"29","author":"Ju\u00e1rez","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.reumae.2021.04.003_bib0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.rdc.2009.03.003","article-title":"Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus","volume":"35","author":"Cuchacovich","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.reumae.2021.04.003_bib0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-019-1997-5","article-title":"Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study","volume":"21","author":"Hsu","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2021.04.003_bib0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/cid\/civ803","article-title":"Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs","volume":"62","author":"Shigayeva","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Rr-8","key":"10.1016\/j.reumae.2021.04.003_bib0110","first-page":"1","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010","volume":"59","author":"Fiore","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.reumae.2021.04.003_bib0115","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3899\/jrheum.160909","article-title":"Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"44","author":"Mohammad","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0120","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/BOR.0000000000000630","article-title":"Infections as triggers of flares in systemic autoimmune diseases: novel innate immunity mechanisms","volume":"31","author":"Torres-Aguilar","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0125","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/0961203317720527","article-title":"Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study","volume":"27","author":"Torres-Ruiz","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.reumae.2021.04.003_bib0130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2008.07.019","article-title":"Infections as triggers and complications of systemic lupus erythematosus","volume":"8","author":"Doria","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.reumae.2021.04.003_bib0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147856","article-title":"Immunogenicity and safety of influenza vaccination in systemic lupus erythematosus patients compared with healthy controls: a meta-analysis","volume":"11","author":"Liao","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.reumae.2021.04.003_bib0140","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001035","article-title":"Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations","volume":"5","author":"Rondaan","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2021.04.003_bib0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0150","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.medcli.2019.01.010","article-title":"Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases","volume":"152","author":"Braga","year":"2019","journal-title":"Med Clin"},{"key":"10.1016\/j.reumae.2021.04.003_bib0155","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.semarthrit.2016.09.009","article-title":"Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: a case-control study","volume":"46","author":"Tadros","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.04.003_bib0160","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/0961203317711009","article-title":"Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study","volume":"27","author":"Lin","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.reumae.2021.04.003_bib0165","series-title":"50: A guideline developers\u2019 handbook","author":"Sign","year":"2011"},{"key":"10.1016\/j.reumae.2021.04.003_bib0170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arbres.2015.04.016","article-title":"Consensus document on prevention and treatment of tuberculosis in patients for biological treatment","volume":"52","author":"Mir Viladrich","year":"2016","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.reumae.2021.04.003_bib0180","first-page":"1996","article-title":"Association between dental caries and pneumonia in patients with systemic lupus erythematosus","volume":"33","author":"Pascual-Ramos","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0185","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MEG.0000000000000280","article-title":"A\u2019 cocoon immunization strategy\u2019 among patients with inflammatory bowel disease","volume":"27","author":"Waszczuk","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0190","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00296-013-2851-8","article-title":"Results of a specific smoking cessation program for patients with arthritis in a rheumatology clinic","volume":"34","author":"Naranjo","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2021.04.003_bib0195","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ejim.2017.05.023","article-title":"Nurse-led vaccination program dramatically improves pneumococcal vaccination coverage among patients with autoimmune inflammatory disorders","volume":"43","author":"Serre","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.reumae.2021.04.003_bib0200","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2764","article-title":"Predictors of major infections in systemic lupus erythematosus","volume":"11","author":"Ruiz-Irastorza","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2021.04.003_bib0205","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/0961203319860579","article-title":"Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort","volume":"28","author":"Pimentel-Quiroz","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.reumae.2021.04.003_bib0210","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s10067-018-4102-6","article-title":"Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality","volume":"37","author":"Teh","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0215","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12879-020-4826-1","article-title":"Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study","volume":"20","author":"Yeo","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0220","first-page":"284","article-title":"[Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients]","volume":"7","author":"G\u00f3mez Reino","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2021.04.003_bib0225","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0230","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2021.04.003_bib0235","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3201\/eid1010.030985","article-title":"Current epidemiology of Pneumocystis pneumonia","volume":"10","author":"Morris","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0240","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1378\/chest.118.3.704","article-title":"Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.reumae.2021.04.003_bib0245","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11926-017-0664-6","article-title":"Pneumocystis Pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented?","volume":"19","author":"Wolfe","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.reumae.2021.04.003_bib0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/PL00021707","article-title":"Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy","volume":"15","author":"Ogawa","year":"2005","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0255","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","article-title":"Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"41","author":"Vananuvat","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.04.003_bib0260","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/RHU.0000000000000215","article-title":"Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid","volume":"21","author":"Chew","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0265","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4065\/71.1.5","article-title":"Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy","volume":"71","author":"Yale","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.reumae.2021.04.003_bib0270","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/339548","article-title":"Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome","volume":"34","author":"Sepkowitz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0275","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3899\/jrheum.090843","article-title":"A survey of rheumatologists\u2019 practice for prescribing pneumocystis prophylaxis","volume":"37","author":"Cettomai","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0280","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0285","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-016-1206-8","article-title":"Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial","volume":"19","author":"Utsunomiya","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2021.04.003_bib0290","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/s10165-012-0730-x","article-title":"A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases","volume":"23","author":"Takenaka","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0295","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3999\/jscpt.45.89","article-title":"A feasibility study assessing tolerability of daily versus twice weekly trimethoprim-sulfamethoxazole regimen for prophylaxis against Pneumocystis pneumonia in patients with systemic autoimmune diseases on glucocorticoid therapy","volume":"45","author":"Yamamoto","year":"2014","journal-title":"Jpn J Clin Pharmacol Ther"},{"key":"10.1016\/j.reumae.2021.04.003_bib0300","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/s10165-012-0625-x","article-title":"Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases","volume":"23","author":"Maezawa","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0305","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.semarthrit.2018.10.018","article-title":"Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs","volume":"48","author":"Schmajuk","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.04.003_bib0310","article-title":"Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","volume":"2014","author":"Stern","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.reumae.2021.04.003_bib0315","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.23822","article-title":"When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases","volume":"59","author":"Suryaprasad","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"12b","key":"10.1016\/j.reumae.2021.04.003_bib0320","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/imj.12599","article-title":"Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014","volume":"44","author":"Cooley","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.reumae.2021.04.003_bib0325","first-page":"255","article-title":"Hepatitis B vaccines. Weekly epidemiological record","volume":"79","author":"World Health Organization","year":"2004","journal-title":"Relev\u00e9 epid\u00e9miologique hebdomadaire"},{"key":"10.1016\/j.reumae.2021.04.003_bib0330","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.idc.2020.02.009","article-title":"Hepatitis B virus reactivation potentiated by biologics","volume":"34","author":"Ogawa","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.reumae.2021.04.003_bib0335","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/rheumatology\/38.10.978","article-title":"Rheumatic disorders developed after hepatitis B vaccination","volume":"38","author":"Maillefert","year":"1999","journal-title":"Rheumatology (Oxford, England)."},{"key":"10.1016\/j.reumae.2021.04.003_bib0340","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1177\/0961203307078225","article-title":"Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus","volume":"16","author":"Kuruma","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.reumae.2021.04.003_bib0345","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/j.1440-1746.2005.03903.x","article-title":"Response to vaccination against hepatitis B in patients with Behcet\u2019s disease","volume":"20","author":"Erkek","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0350","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3949\/ccjm.85a.17017","article-title":"What is the hepatitis B vaccination regimen in chronic kidney disease?","volume":"85","author":"Ong","year":"2018","journal-title":"Clevel Clin J Med"},{"key":"10.1016\/j.reumae.2021.04.003_bib0355","series-title":"Epidemiology and Prevention of Vaccine-Preventable Diseases","year":"2015"},{"key":"10.1016\/j.reumae.2021.04.003_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.reumae.2021.04.003_bib0365","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3899\/jrheum.110289","article-title":"Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases","volume":"38","author":"Kato","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0370","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10067-013-2450-9","article-title":"Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy\u2014a report of long-term follow-up of serial cases and literature review","volume":"33","author":"Xuan","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0375","doi-asserted-by":"crossref","first-page":"212","DOI":"10.7861\/clinmedicine.18-3-212","article-title":"Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians","volume":"18","author":"Koffas","year":"2018","journal-title":"Clin Med"},{"key":"10.1016\/j.reumae.2021.04.003_bib0380","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00296-008-0823-1","article-title":"Management of hepatitis B reactivation in patients with lupus nephritis","volume":"29","author":"Tse","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2021.04.003_bib0385","first-page":"306","article-title":"High hepatitis B virus load in a patient with severe polyarthritis nodosa","volume":"10","author":"Ghorbani","year":"2010","journal-title":"Hepat Mon"},{"key":"10.1016\/j.reumae.2021.04.003_bib0390","first-page":"22","article-title":"Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases","volume":"60","author":"Zingarelli","year":"2008","journal-title":"Reumatismo"},{"key":"10.1016\/j.reumae.2021.04.003_bib0395","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00042737-200205000-00016","article-title":"Hepatitis B associated fulminant polyarteritis nodosa: successful treatment with pulse cyclophosphamide, prednisolone and lamivudine following emergency surgery","volume":"14","author":"Lau","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0400","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.09.2009.2273","article-title":"Outcome in a patient with systemic lupus erythematosus and concurrent chronic hepatitis B infection","volume":"2010","author":"Marinchev","year":"2010","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.reumae.2021.04.003_bib0405","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V100.2.391","article-title":"Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers","volume":"100","author":"Shibolet","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.reumae.2021.04.003_bib0410","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.dld.2016.03.018","article-title":"Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie \u2014 GISC","volume":"48","author":"Mazzaro","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0415","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5152\/eurjrheum.2017.17003","article-title":"Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series","volume":"4","author":"Abdulaziz","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0420","first-page":"55","article-title":"Successful treatment of refractory Beh\u00e7et\u2019s disease with the TNF-alpha blocker infliximab","volume":"6","author":"Jalili","year":"2009","journal-title":"Iran J Immunol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0425","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3350\/cmh.2016.0024","article-title":"Prevention of Hepatitis B reactivation in the setting of immunosuppression","volume":"22","author":"Pattullo","year":"2016","journal-title":"Clin Mol Hepatol"},{"issue":"Suppl 4","key":"10.1016\/j.reumae.2021.04.003_bib0430","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1093\/cid\/ciw043","article-title":"Hepatitis B virus reactivation in the setting of cancer chemotherapy and other immunosuppressive drug therapy","volume":"62","author":"Gonzalez","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0435","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.reumae.2021.04.003_bib0440","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0445","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/jnci\/87.11.796","article-title":"Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group","volume":"87","author":"Bosch","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.reumae.2021.04.003_bib0450","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10067-010-1606-0","article-title":"Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review","volume":"30","author":"Santana","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0455","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/BOR.0000000000000648","article-title":"Malignancies in systemic lupus erythematosus: an update","volume":"31","author":"Ladouceur","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0460","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13075-018-1760-3","article-title":"The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis","volume":"20","author":"Song","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2021.04.003_bib0465","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/rheumatology\/keq304","article-title":"Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia","volume":"50","author":"Liu","year":"2011","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0470","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.autrev.2014.03.001","article-title":"Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature","volume":"13","author":"Zard","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.reumae.2021.04.003_bib0475","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/annrheumdis-2013-204993","article-title":"Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study","volume":"74","author":"Kim","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0480","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/art.22667","article-title":"High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients","volume":"57","author":"Nath","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.04.003_bib0485","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3346\/jkms.2010.25.10.1431","article-title":"Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus","volume":"25","author":"Lee","year":"2010","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.reumae.2021.04.003_bib0490","first-page":"302","article-title":"Comparison of human papillomavirus testing and cervical cytology with colposcopic examination and biopsy in cervical cancer screening in a cohort of patients with Sjogren\u2019s syndrome","volume":"28","author":"Cirpan","year":"2007","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0495","first-page":"184","article-title":"Human papillomavirus infection and cervical lesions in rheumatic diseases: a systematic review","volume":"41","author":"Raposo","year":"2016","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.reumae.2021.04.003_bib0500","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","article-title":"Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study","volume":"72","author":"Mok","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0505","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1016\/j.vaccine.2018.04.056","article-title":"Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus","volume":"36","author":"Mok","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.reumae.2021.04.003_bib0510","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.vaccine.2017.04.001","article-title":"The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus","volume":"35","author":"Dhar","year":"2017","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.reumae.2021.04.003_bib0515","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1080\/21645515.2018.1469592","article-title":"The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus","volume":"14","author":"Dhar","year":"2018","journal-title":"Human Vaccin Immunother"},{"key":"10.1016\/j.reumae.2021.04.003_bib0520","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/0961203311429556","article-title":"Systemic lupus erythematosus following HPV immunization or infection?","volume":"21","author":"Soldevilla","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.reumae.2021.04.003_bib0525","first-page":"545","article-title":"Autoimmune\/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: a call for personalised medicine","volume":"33","author":"Anaya","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0530","first-page":"56","article-title":"[Immunisation schedule of the Spanish Association of Paediatrics: 2019 recommendations]","volume":"90","author":"Moreno-P\u00e9rez","year":"2019","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0535","unstructured":"Grupo de trabajo vacunaci\u00f3n en poblaci\u00f3n adulta y grupos de riesgo de laPonencia de Programa y Registro de Vacunaciones. Vacunaci\u00f3n en grupos deriesgo de todas las edades y en determinadas situaciones. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministeriode Sanidad, Consumo y Bienestar Social, julio 2018."},{"key":"10.1016\/j.reumae.2021.04.003_bib0540","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0819","article-title":"Effect of human papillomavirus vaccine to interrupt recurrence of vulvar and anal neoplasia (VIVA): a trial protocol","volume":"2","author":"Stankiewicz Karita","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.reumae.2021.04.003_bib0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223658","article-title":"The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia","volume":"14","author":"Mahumud","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.reumae.2021.04.003_bib0550","doi-asserted-by":"crossref","first-page":"ofu024","DOI":"10.1093\/ofid\/ofu024","article-title":"Rates of pneumococcal disease in adults with chronic medical conditions","volume":"1","author":"Shea","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0555","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/jech-2011-200168","article-title":"Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses","volume":"66","author":"Wotton","year":"2012","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.reumae.2021.04.003_bib0560","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/kew211","article-title":"Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis","volume":"55","author":"Pug\u00e8s","year":"2016","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0565","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.autrev.2018.08.002","article-title":"Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: an evidence-informed and PRISMA compliant systematic review and meta-analysis","volume":"18","author":"Adawi","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.reumae.2021.04.003_bib0570","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/0961203317703495","article-title":"A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus","volume":"26","author":"Chatham","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.reumae.2021.04.003_bib0575","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/art.1780231111","article-title":"Immunization of patients with Sj\u00f6gren\u2019s syndrome with pneumococcal polysaccharide vaccine: a randomized trial","volume":"23","author":"Karsh","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.04.003_bib0580","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41927-018-0019-6","article-title":"Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sj\u00f6gren\u2019s syndrome without disease modifying treatment","volume":"2","author":"Nived","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0585","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3899\/jrheum.081227","article-title":"Antibody response to pneumococcal polysaccharide vaccine in systemic sclerosis","volume":"36","author":"Mercado","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0590","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/rheumatology\/kex471","article-title":"Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis","volume":"57","author":"Hesselstrand","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0595","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jbspin.2016.09.019","article-title":"Failure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: The Pneumovas Pilot 1 study","volume":"84","author":"Groh","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.reumae.2021.04.003_bib0600","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1016\/j.vaccine.2017.05.044","article-title":"Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy","volume":"35","author":"Nived","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.reumae.2021.04.003_bib0605","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/acr.22757","article-title":"Association of low B cell count and IgG levels with infection, and poor vaccine response with all-cause mortality in an immunosuppressed vasculitis population","volume":"68","author":"David Morgan","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.reumae.2021.04.003_bib0610","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/infdis\/jiy493","article-title":"Subclinical reactivation of cytomegalovirus drives CD4+CD28null T-cell expansion and impaired immune response to pneumococcal vaccination in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"219","author":"Chanouzas","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0615","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/ker388","article-title":"Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behcet\u2019s disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine","volume":"51","author":"H\u00fcgle","year":"2012","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0620","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/0036933018801215","article-title":"Behcet\u2019s disease and severe inflammatory reaction to 23-valent pneumococcal polysaccharide vaccine: a case report and review of literature","volume":"63","author":"Saeidinejad","year":"2018","journal-title":"Scottish Med J"},{"key":"10.1016\/j.reumae.2021.04.003_bib0625","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1086\/338043","article-title":"Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus","volume":"34","author":"Elkayam","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0630","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/art.30325","article-title":"Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study","volume":"63","author":"Gabay","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.04.003_bib0635","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/ard.2011.150250","article-title":"Immunogenicity and safety of the 2009 non-adjuvanted influenza A\/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases","volume":"70","author":"Saad","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.reumae.2021.04.003_bib0640","doi-asserted-by":"crossref","first-page":"e3637","DOI":"10.1097\/MD.0000000000003637","article-title":"Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination? A systematic review and meta-analysis","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"issue":"1 Suppl 70","key":"10.1016\/j.reumae.2021.04.003_bib0645","first-page":"S83","article-title":"Immunogenicity and safety of seasonal and 2009 pandemic A\/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients","volume":"30","author":"Kostianovsky","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0650","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1002\/art.30576","article-title":"Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus","volume":"63","author":"Mathian","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.04.003_bib0655","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1620\/tjem.229.29","article-title":"Influenza vaccination in autoimmune rheumatic disease patients","volume":"229","author":"Milanovic","year":"2013","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.reumae.2021.04.003_bib0660","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1016\/j.vaccine.2013.05.095","article-title":"Control of humoral immunity and auto-immunity by the CXCR4\/CXCL12 axis in lupus patients following influenza vaccine","volume":"31","author":"Launay","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.reumae.2021.04.003_bib0665","doi-asserted-by":"crossref","first-page":"37817","DOI":"10.1038\/srep37817","article-title":"Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study","volume":"6","author":"Chang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.reumae.2021.04.003_bib0670","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1093\/rheumatology\/kex330","article-title":"Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis","volume":"57","author":"Sampaio-Barros","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"issue":"2 Suppl 71","key":"10.1016\/j.reumae.2021.04.003_bib0675","first-page":"S7","article-title":"Vaccination against influenza in patients with systemic sclerosis","volume":"30","author":"Litinsky","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0680","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1016\/j.vaccine.2009.01.078","article-title":"Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients","volume":"27","author":"Setti","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.reumae.2021.04.003_bib0685","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.vaccine.2013.01.057","article-title":"Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sj\u00f6gren\u2019s syndrome","volume":"31","author":"Pasoto","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.reumae.2021.04.003_bib0690","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1136\/annrheumdis-2016-210509","article-title":"H1N1 vaccination in Sj\u00f6gren\u2019s syndrome triggers polyclonal B cell activation and promotes autoantibody production","volume":"76","author":"Brauner","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0695","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.vaccine.2012.10.063","article-title":"Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease","volume":"31","author":"Shinjo","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.reumae.2021.04.003_bib0700","first-page":"583","article-title":"Influenza A H1N1\/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy","volume":"30","author":"Guissa","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0705","doi-asserted-by":"crossref","first-page":"129","DOI":"10.6061\/clinics\/2013(02)OA02","article-title":"Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy","volume":"68","author":"Miossi","year":"2013","journal-title":"Clinics (Sao Paulo, Brazil)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0710","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/nep.12416","article-title":"Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"20","author":"Jeffs","year":"2015","journal-title":"Nephrology (Carlton, Vic)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0715","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/ard.2008.092924","article-title":"Wegener\u2019s granulomatosis patients show an adequate antibody response to influenza vaccination","volume":"68","author":"Holvast","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0720","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/ard.2009.112813","article-title":"Cell-mediated immune responses to influenza vaccination in Wegener\u2019s granulomatosis","volume":"69","author":"Holvast","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0725","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/ker389","article-title":"Protective effect of A\/H1N1 vaccination in immune-mediated disease\u2014a prospectively controlled vaccination study","volume":"51","author":"Adler","year":"2012","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0730","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1002\/art.30388","article-title":"Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features","volume":"63","author":"Crowe","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.04.003_bib0735","first-page":"723","article-title":"Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination","volume":"31","author":"Muller","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0740","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/rheumatology\/ker427","article-title":"Influenza A\/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?","volume":"51","author":"Borba","year":"2012","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2021.04.003_bib0745","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3899\/jrheum.111587","article-title":"Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial","volume":"39","author":"Chatham","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0750","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/acr.20599","article-title":"Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus","volume":"63","author":"Urowitz","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.reumae.2021.04.003_bib0755","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/0961203311429554","article-title":"Influenza vaccination can induce new-onset anticardiolipins but not \u03b22-glycoprotein-I antibodies among patients with systemic lupus erythematosus","volume":"21","author":"Vista","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.reumae.2021.04.003_bib0760","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/ndt\/gfm640","article-title":"Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis","volume":"23","author":"Stassen","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.reumae.2021.04.003_bib0765","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/cid\/ciw855","article-title":"Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: results of TRANSGRIPE 1-2, a randomized controlled clinical trial","volume":"64","author":"Cordero","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"3 Pt 1","key":"10.1016\/j.reumae.2021.04.003_bib0770","first-page":"795","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.reumae.2021.04.003_bib0775","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.rhu.0000221794.24431.36","article-title":"Pneumocystis carinii pneumonia in patients with connective tissue disease","volume":"12","author":"Li","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0780","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/RHU.0b013e31829d5017","article-title":"Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan","volume":"19","author":"Weng","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0785","first-page":"671","article-title":"Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience","volume":"35","author":"Mecoli","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0790","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q","article-title":"Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner\u2019s granulomatosis undergoing immunosuppressive therapy","volume":"43","author":"Chung","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2021.04.003_bib0795","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.04.003_bib0800","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex differences in vaccine-induced humoral immunity","volume":"41","author":"Fischinger","year":"2019","journal-title":"Semin Immunopathol"},{"issue":"2","key":"10.1016\/j.reumae.2021.04.003_bib0805","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/CVI.05208-11","article-title":"Immunogenicity of the quadrivalent human papillomavirus (type 6\/11\/16\/18) vaccine in males 16 to 26 years old","volume":"19","author":"Hillman","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.reumae.2021.04.003_bib0810","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1016\/j.vaccine.2015.08.072","article-title":"Immunogenicity and safety of Gardasil among mid-adult aged men (27\u201345 years)\u2014the MAM study","volume":"33","author":"Giuliano","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.reumae.2021.04.003_bib0815","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1546-0096-11-29","article-title":"Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years","volume":"11","author":"Soybilgic","year":"2013","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321001672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321001672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:01:56Z","timestamp":1761879716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574321001672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":163,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2173574321001672"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2021.04.003","relation":{},"ISSN":["2173-5743"],"issn-type":[{"value":"2173-5743","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for prevention of infection in systemic autoimmune rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2021.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2021.04.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}